<DOC>
	<DOC>NCT00393484</DOC>
	<brief_summary>Entecavir, 0.5 mg daily, will have clinical efficacy (assessed as an undetectable hepatitis B DNA, &lt;300 copies/mL, by Roche Comprehensive Bio-Analytical System Amplicor polymerase chain reaction assay) that is comparable (noninferior) and potentially superior to lamivudine, 100 mg once daily, in adults with hepatitis B e antigen-negative chronic hepatitis B virus infection.</brief_summary>
	<brief_title>A Study in Korea of Entecavir Versus Lamivudine in Adults With Chronic Hepatitis B Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Nucleoside and nucleotidenaive subjects with chronic HBV infection Hepatitis B Surface antigen(HBsAg)positive ≥6 months Detectable HBsAg HBV DNA ≥ 105 copies/mL by PCR ALT 1.3 to 10 x the ULN HBeAg negative, antihepatitis B Virus E antigen antibody (antiHBeAb) positive status</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>